Cui Cui

Cui Cui is the head of healthcare research for Asia at an unspecified firm. She is newsworthy due to her analysis of the impact of US reshoring efforts on Chinese contract drug manufacturers. According to Cui Cui, companies like WuXi AppTec, WuXi Biologics, and WuXi XDC face a less certain long-term revenue outlook as US pharmaceutical companies bring production in-house, driven by rising US-China tensions. While near-term earnings for these Chinese companies remain largely secured, Cui Cui suggests that visibility beyond the immediate future is limited. Her analysis highlights the vulnerability of the Chinese contract drug manufacturing sector to geopolitical factors and the shifting strategies of US pharmaceutical companies. This is significant as it points to potential economic challenges for China's pharmaceutical industry and the need for adaptation in the face of evolving global supply chains.